Pulmonary Medicine Patiala

http://chestgmcpatiala.weebly.com/lohri-celebration.html

LOHRI CELEBRATION Department Of Pulmonary Medicine

Happy new year 😄

COPD 2014 Update

http://www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdf

http://www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdf

Teachers Day

Tuberculosis Update

Spotter1
A fifteen-year-old boy was investigated for failure to thrive. He was totally asymptomatic and no respiratory complaint at the time of evaluation. He had received two courses of anti tuberculosis treatment (2007 and 2009) elsewhere with the diagnosis of Miliary tuberculosis based on radiological findings. Clinical examination did not reveal any abnormality.
His CBC, electrolytes and calcium were normal. Ultrasound of abdomen was normal. Flow volume loop showed mild restriction. Serial chest X-rays from 2007 showed bilateral diffuse micronodular calcific shadows more toward the mid and lower zones .HRCT scan showed bilateral diffuse micronodular opacities distributed predominantly over basal and posterior regions with thickening of interlobar septa.

Spot the diagnosis...

Moxonidine :new-generation centrally-acting antihypertensive drug licensed for the treatment of mild to moderate essential hypertension.
is a selective agonist at the imidazoline receptor subtype 1 (I1). This receptor subtype is found in both the rostral ventro-lateral pressor and ventromedial depressor areas of the medulla oblongata. Moxonidine therefore causes a decrease in sympathetic nervous system activity and, therefore, a decrease in blood pressure.
Compared to the older central-acting antihypertensives, moxonidine binds with much greater affinity to the imidazoline I1-receptor than to the α2-receptor. In contrast, clonidine binds to both receptors with equal affinity.
In addition, moxonidine may also promote sodium excretion, improve insulin resistance and glucose tolerance and protect against hypertensive target organ damage, such as kidney disease and cardiac hypertrophy.

Riociguat, which relaxes pulmonary blood vessels via a novel mechanism, improved 6-minute walk distances in patients with pulmonary arterial hypertension (PAH) and in those with chronic thromboembolic pulmonary hypertension (CTEPH) in separate placebo-controlled trials, according to Hossein Ardeschir Ghofrani, MD, of University Hospital of Giessen and Marburg in Giessen, Germany